Dose of intravenous immunoglobulin and patient survival in SJS and toxic epidermal necrolysis

Expert Review of Dermatology

Volumn 2, Issue 3, 2007, Pages 299-303

  Trent, Jennifer T ^a   Ma, Fangchao ^a   Kerdel, Francisco ^a   Fien, Sari ^a   French, Lars E ^b   Romanelli, Paolo ^a   Kirsner, Robert S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Intravenous immunoglobulin; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ANTICONVULSIVE AGENT; FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONAMIDE;

ADJUVANT THERAPY; AGE; APOPTOSIS; ARTICLE; BODY SURFACE; BULLOUS PEMPHIGOID; CLINICAL TRIAL; DERMATOMYOSITIS; DOSE CALCULATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG USE; EXPERIENCE; HUMAN; HYPERSENSITIVITY REACTION; KERATINOCYTE; LOGISTIC REGRESSION ANALYSIS; MEDICAL LITERATURE; MEDLINE; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PUBLICATION; STATISTICAL ANALYSIS; STEVENS JOHNSON SYNDROME; SURVIVAL; SURVIVAL RATE; TOXIC EPIDERMAL NECROLYSIS;

EID: 34250312076     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.2.3.299     Document Type: Article

References (21)

1. Roujeau JC, Kelly JP, Naldi L. Medication use and the risk of Stevens Johnson syndrome and toxic epidermal necrolysis. N. Engl. J. Med. 333, 1600-1609 (1995).
2. Wolkenstein P, Latarjet J, Roujeau JC. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352, 1586-1589 (1998).
3. Lipper GM, Arndt KA, Dover JS. Recent therapeutic advances in dermatology. JAMA 283, 175-177 (2000).
4. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens Johnson syndrome. Arch. Dermatol. 136, 232-237 (2000).
5. Viard I, Wehrli P, Bullani R. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490-493 (1998).
6. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch. Dermatol. 139, 39-43 (2003).
7. Prins C, Kerdel FA, Padilla S et al. Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch. Dermatol. 139, 26-32 (2003).
8. Bachot N, Revuz J, Roujeau JC. Intravenous immunglobulin treatment for Stevens Johnson syndrome and toxic epidermal necrolysis. Arch. Dermatol. 139, 33-36 (2003).
9. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high dose immunoglobulins: our experience. Dermatology 203, 45-49 (2001).
10. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 112, 1430-1436 (2003).
11. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm. Venereol. 83, 430-432 (2003).
12. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. JAAD 47, 548-552 (2002).
13. Morici MV, Galen WK, Shetty AK et al. Intravenous immunoglobulin therapy for children with Stevens Johnson syndrome. J. Rheumatol. 27, 2494-2497 (2000).
14. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J. Burn Care Rehabil. 25, 81-88 (2004).
15. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J. Burn Care Rehabil. 24, S88 (2003).
16. Tan AW, Thong BY, Yip LW, Chng HH, Ng SK. High dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J. Dermatol. 32(1), 1-6 (2005).
17. Al-Mutairi N, Arun J, Osama NE et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int. J. Dermatol. 43(11), 847-851 (2004).
18. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity of illness score for toxic epidermal necrolysis. J. Invest. Dermatol. 115, 149-153 (2000).
19. Jolles S, Hughes J, Whittaker S. Dermatologic uses of high dose intravenous immunoglobulin. Arch. Dermatol. 134, 80-86 (1998).
20. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. SCORTEN accurately predicts mortality in patients with toxic epidermal necrolysis in the United States. Arch. Dermatol. 140, 890-892 (2004).
21. Dickersin K, Rennie D. Registering clinical trials. JAMA 290, 516-523 (2003).